A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

PHASE3CompletedINTERVENTIONAL
Enrollment

4,156

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Type 2 Diabetes
Interventions
DRUG

ITCA 650

ITCA 650

OTHER

ITCA placebo

ITCA placebo

Trial Locations (42)

2193

Johannesburg

2650

Hvidovre

4002

Plovdiv

15236

Study Site, Pittsburgh

15401

Study Site, Uniontown

27103

Study Site, Winston-Salem

29651

Study Site, Greer

34098

Istanbul

34208

Study Site, Bradenton

34652

Study Site, New Port Richey

34684

Study Site, Palm Harbor

37431

Bad Lauterberg im Harz

43213

Study Site, Columbus

45005

Study Site, Franklin

45236

Study Site, Cincinnati

46123

Study Site, Avon

46131

Study Site, Franklin

46140

Study Site, Greenfield

47304

Study Site, Muncie

47714

Study Site, Evansville

48307

Study Site, Rochester

59101

Study Site, Billings

60634

Study Site, Chicago

63141

Study Site, St Louis

67114

Study Site, Newton

67205

Study Site, Wichita

67207

Study Site, Wichita

70006

Study Site, Metaire

75230

Dallas

75231

Study Site, Dallas

78229

Study Site, San Antonio

78745

Study Site, Austin

85224

Study Site, Chandler

89128

Study Site, Las Vegas

89148

Las Vegas

90100

Oulu

90806

Study Site, Long Beach

92114

Study SIte, San Diego

93041

Study Site, Port Hueneme

94545

Intarcia Therapeutics, Inc, Hayward

81-717

Sopot

03659

Martin

Sponsors
All Listed Sponsors
lead

Intarcia Therapeutics

INDUSTRY